NEOPROBE CORP
CIK:0000810509|SEC Filings
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) |
3 Months Ended | 9 Months Ended | ||||
|---|---|---|---|---|---|---|
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
|||
| Revenue: | ||||||
| Revenue from contract with customer | $ 0 | $ 7,516 | $ 0 | $ 14,035 | ||
| Grant and other revenue | 0 | 0 | 0 | 51,007 | ||
| Total Revenue | 0 | 7,516 | 0 | 65,042 | ||
| Cost of revenue | 0 | 1,432 | 0 | 1,905 | ||
| Reserve for expiring inventory | 0 | 133,006 | 0 | 133,006 | ||
| Gross profit | 0 | (126,922) | 0 | (69,869) | ||
| Research and development | 829,613 | 1,186,419 | 3,203,331 | 4,079,661 | ||
| Selling, general and administrative | 1,301,725 | 3,637,450 | 3,778,074 | 6,703,145 | ||
| Total operating expenses | 2,131,338 | 4,823,869 | 6,981,405 | 10,782,806 | ||
| Loss from operations | [1] | (2,131,338) | (4,950,791) | (6,981,405) | (10,852,675) | |
| Other (expense) income: | ||||||
| Interest (expense) income, net | (102,514) | (765,456) | 248,671 | (852,702) | ||
| Gain on amendment of contracts | 0 | 0 | 1,226,432 | 0 | ||
| Gain on sale of non-financial asset – NAV4694 | 0 | 0 | 750,000 | 0 | ||
| Loss on extinguishment of debt | 0 | 0 | (185,056) | 0 | ||
| Other, net | (21,487) | 8,422 | (183,495) | 10,489 | ||
| Total other (expense) income, net | (124,001) | (757,034) | 1,856,552 | (841,853) | ||
| Loss from continuing operations | (2,255,339) | (5,707,825) | (5,124,853) | (11,694,528) | ||
| Discontinued operations, net of tax effect: | ||||||
| Gain on discontinued operations – Lymphoseek® | 0 | 0 | 7,425,000 | 0 | ||
| Net income (loss) | (2,255,339) | (5,707,825) | 2,300,147 | (11,694,528) | ||
| Net income attributable to noncontrolling interest | 1 | 0 | 2 | 4 | ||
| Preferred stock dividends | 0 | 0 | (68,937) | 0 | ||
| Deemed dividend on preferred stock exchanged | 0 | (2,037,886) | (138,045) | (2,037,886) | ||
| Net (loss) income attributable to common stockholders | $ (2,255,338) | $ (7,745,711) | $ 2,093,167 | $ (13,732,410) | ||
| Continuing operations (in dollars per share) | $ (0.02) | $ (0.25) | $ (0.09) | $ (0.45) | ||
| Discontinued operations (in dollars per share) | 0 | 0 | 0.12 | 0 | ||
| Attributable to common stockholders (in dollars per share) | $ (0.02) | $ (0.25) | $ 0.03 | $ (0.45) | ||
| Weighted average shares outstanding (in shares) | 99,364,154 | 30,732,001 | 60,331,296 | 30,404,789 | ||
| (Loss) income per common share (basic and diluted) | ||||||
| Net (loss) income attributable to common stockholders | $ (2,255,338) | $ (7,745,711) | $ 2,093,167 | $ (13,732,410) | ||
| ||||||